Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer
Rafael Holdings, Inc. Class B (RFL)
NASDAQ:AMEX Investor Relations:
morningstar.com/funds/xnas/rytnx/quote.html
Company Research
Source: GlobeNewswire
Cranbury, NJ, March 24, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has enrolled more than 75% of the 500 patients needed for its pivotal Phase 3 clinical trial for metastatic pancreatic cancer (AVENGER 500), which is evaluating the efficacy and safety of Rafael’s lead compound CPI-613®? (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy. “We are continuing to enroll patients ahead of schedule, as the patients in our trials suffer from life-threatening diseases and are in dire need of treatment; patient safety is our top priority,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “In order to support our clinical trial sites and enrolled patients during this unsettling and unprecedented time, we have established a COVID-19 task force to closely monitor our clinical trials and make changes as needed.
Show less
Read more
Impact Snapshot
Event Time:
RFL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RFL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RFL alerts
High impacting Rafael Holdings, Inc. Class B news events
Weekly update
A roundup of the hottest topics
RFL
News
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsGlobeNewswire
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTXAccesswire
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTXAccesswire
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTXAccesswire
RFL
Sec Filings
- 11/19/24 - Form DEF
- 11/7/24 - Form 10-K
- 11/7/24 - Form 8-K
- RFL's page on the SEC website